Skip to content

Clinical trial to observe the safety and effectiveness of acotiamide in patients with functional dyspepsia

Real world, Non-interventional, Observational Study of acotiamide hydrochloride hydrate in functional dyspepsia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/11/010421
Enrollment
160
Registered
2017-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with functional dyspepsia diagnosed by rome 3 criteria

Interventions

None listed

Sponsors

Dr Reddys Laboratories Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients clinically diagnosed with functional dyspepsia where physician has taken decision to prescribe acotiamide hydrochloride hydrate. 2.Patients with Functional Dyspepsia as defined by Rome III criteria Diagnostic criteria Must include: One or more of the following: a. Bothersome postprandial fullness b. Early satiation c. Epigastric pain d. Epigastric burning and No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Exclusion criteria

Exclusion criteria: 1. Patients with a known or suspected hypersensitivity to acotiamide or to any ingredients of the formulation 2. Patients on cholinergic drugs as part of therapy 3. Patients on prokinetics as a part of therapy 4. Structural lesion evident in endoscopy 5. Coexisting Irritable bowel syndrome 6. Heartburn in past 12 weeks 7. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Effectiveness of acotiamide hydrochloride hydrate in overall treatment efficacy, will be recorded using the 7 point Likert scale questionnaire at the end of 2 weeks and 4 weeks compared to baseline. Patients whose symptoms are â??Extremely improved â??and â??improvedâ?? in Likert scale are to be considered as responders Timepoint: 2 and 4 weeks

Secondary

MeasureTime frame
Effectiveness of acotiamide hydrochloride hydrate in elimination of all three symptoms (post prandial fullness, upper abdominal bloating, early satiety) using a symptom scale (severe-3,moderare-2,mild-1,none-0) Disease specific quality of life index using SF NDI ( short form Napean Dyspepsia Index for QOL measurement) at the end of 2 weeks and 4 weeks compared to baseline. Timepoint: 2 and 4 weeks

Countries

India

Contacts

Public ContactV Krishna chaitanya

Gandhi hospital

shravangastro@gmail.com04027508388

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 5, 2026